Tripeptidyl Peptidase-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Tripeptidyl-Peptidase 2 (TPP2, UniProt P29144), expressed in HEK293 cells. Suitable for enzymatic activity assays, inhibitor profiling, and antibody validation in the ubiquitin-proteasome and amino acid homeostasis research context.
Expression system
HEK293
Cat. #
REC-TripeptidylPeptidase2

In stock

SKU
REC-TripeptidylPeptidase2
$498.00

Target Overview

Tripeptidyl-Peptidase 2 (TPP2; UniProt P29144) is a cytosolic serine protease (EC 3.4.14.10) encoded by the TPP2 gene that sequentially releases N-terminal tripeptides from polypeptide substrates. The full-length human protein spans 1,249 amino acids and assembles into large oligomeric complexes — among the largest non-ribosomal protein complexes characterised in mammalian cells — a structural feature that distinguishes TPP2 from other cytosolic peptidases and is relevant to its activity profile in biochemical assays. This recombinant is produced in HEK293 cells, providing a mammalian glycosylation and folding environment appropriate for a protein whose native function depends on correct oligomeric assembly. HEK293-derived material is generally preferred over bacterial or insect-cell preparations for serine protease work where post-translational processing affects catalytic efficiency or inhibitor binding geometry. In the laboratory, recombinant TPP2 is most commonly employed in fluorogenic substrate cleavage assays — typically using Ala-Ala-Phe-AMC or related tripeptide-AMC substrates — to quantify exopeptidase activity and determine inhibitor IC₅₀ values. It is also used as a defined antigen for antibody characterisation: researchers pairing this recombinant with the matched Triple Point Biologics anti-TPP2 antibody (RP-Tripeptidyl Peptidase2) can establish dose-response controls in Western blot experiments and confirm immunoreactivity against correctly folded human TPP2 protein. Additional applications include substrate-specificity profiling by mass spectrometry, biochemical reconstitution of post-proteasomal proteolytic cascades, and protein–protein interaction studies examining TPP2's association with 26S proteasome components.

Background

Tripeptidyl-Peptidase 2 (TPP2) functions as a cytosolic exopeptidase operating downstream of the 26S proteasome in the ubiquitin-proteasome pathway. After the proteasome degrades ubiquitin-tagged substrates into short peptide fragments, TPP2 trims these fragments further by releasing successive N-terminal tripeptides, contributing to the recycling of amino acids back into the free pool. This role in intracellular amino acid homeostasis has been confirmed in biochemical reconstitution studies and makes TPP2 a relevant research target for groups studying cellular protein quality control, nutrient sensing, and proteostasis. The enzyme belongs to the subtilisin-type (clan SB) family of serine proteases, distinguished by an unusual spindle-shaped oligomeric architecture that has been resolved structurally. Understanding how oligomerisation regulates TPP2 activity — and how disruption of assembly affects its enzymatic output — is an active area of structural biology research. Recombinant preparations are central to these efforts, enabling controlled in vitro assembly experiments and kinetic characterisation under defined conditions. TPP2 has been studied as a research target in immunology contexts, where it is implicated in trimming peptide ligands that are subsequently loaded onto MHC class I molecules for antigen presentation. Published studies have investigated how modulation of TPP2 activity alters the peptide repertoire presented at the cell surface, with implications for understanding T-cell recognition. In separate lines of published research, TPP2 has been identified as a candidate gene in analyses of inborn errors of immunity — for example, Barros de Oliveira Sá et al. (2026, PMID 42190421) identified rare TPP2 variants in a cohort study examining genetic contributors to severe COVID-19 susceptibility — framing TPP2 as a research subject in primary immunodeficiency and antiviral immune response investigations. TPP2 expression has also been noted in transcriptomic studies of conditions including postpartum depression and metabolic disorders, where the gene appears in immune-infiltration and exosome-associated gene signatures. These observations position TPP2 as an interesting research target at the intersection of proteolysis, immune function, and metabolic regulation, though the mechanistic links in most of these contexts remain under active investigation. For researchers requiring a matched antibody reagent, the Triple Point Biologics anti-TPP2 antibody (RP-Tripeptidyl Peptidase2) — validated for Western blot against human TPP2 — can be used alongside this recombinant for antibody performance verification and signal calibration.

Applications

  • Fluorogenic exopeptidase activity assay using Ala-Ala-Phe-AMC or analogous tripeptide-AMC substrates
  • Inhibitor IC50 determination and dose-response profiling against serine protease inhibitor libraries
  • Antibody validation positive control for Western blot using matched anti-TPP2 antibody (RP-Tripeptidyl Peptidase2)
  • Substrate specificity profiling by mass spectrometry to map N-terminal tripeptide release patterns
  • Biochemical reconstitution of post-proteasomal proteolytic cascades in cell-free systems
  • MHC class I peptide-trimming assays to examine antigen presentation pathway contributions
  • Protein–protein interaction studies examining TPP2 association with proteasome subunits or regulatory factors
  • Oligomeric assembly and structural characterisation experiments under defined in vitro conditions

References

  1. Barros de Oliveira Sá MV et al. Rare variants in inborn errors of immunity genes in young adults with severe COVID-19: Insights from a Brazilian cohort. Hum Immunol. 2026. doi:10.1016/j.humimm.2026.111764. PMID: 42190421
  2. Yang P et al. Identification and functional analysis of two novel tpp genes in Bacillus thuringiensis HSY91. Pestic Biochem Physiol. 2026. doi:10.1016/j.pestbp.2026.107157. PMID: 42264755
  3. He J et al. Gene signatures associated with exosomes as diagnostic markers of postpartum depression and their role in immune infiltration. Front Endocrinol (Lausanne). 2025. doi:10.3389/fendo.2025.1542327. PMID: 40747300
  4. Mir R et al. A rare likely pathogenic HLA-DRB1 variant with compromised immunity in severe COVID-19 patient and in-hospital mortality. Per Med. 2025. doi:10.1080/17410541.2025.2538424. PMID: 40704829
  5. Yuan YT et al. Filamentous chemokine CCL5 structure and the functional aspects. Sci Rep. 2025. doi:10.1038/s41598-025-98114-9. PMID: 40253490

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight does recombinant Tripeptidyl Peptidase-2 run at on SDS-PAGE or Western blot?

The full-length human TPP2 protein (UniProt P29144) is 1,249 amino acids, predicting an unmodified MW of ~138 kDa. HEK293-expressed material carries mammalian glycosylation, so the observed band on reducing SDS-PAGE typically migrates at approximately 140–145 kDa. Under non-denaturing conditions native TPP2 forms large oligomeric complexes (>1 MDa), so non-reducing or native PAGE will give a very different picture. For routine SDS-PAGE positive-control lanes, load under fully denaturing, reducing conditions and expect a single band in the 140–145 kDa range, confirmed at >90% purity by Coomassie or silver stain.

Is this recombinant TPP2 the full-length protein or a catalytic fragment, and does isoform matter for my assay?

This preparation is full-length human TPP2 (residues 1–1,249), expressed in HEK293 cells. A shorter splice variant (sometimes called TPP2-short) exists but lacks physiological relevance in most cytosolic degradation studies. For fluorogenic exopeptidase assays measuring sequential tripeptide release, full-length material is essential because oligomeric assembly — dependent on the C-terminal domain — is required for full catalytic efficiency. If your assay involves monitoring complex formation by native PAGE or size-exclusion chromatography, confirm oligomerization is intact prior to kinetic measurements; the HEK293 expression system is chosen specifically to support correct folding and assembly.

What substrates does recombinant Tripeptidyl Peptidase-2 cleave and which fluorogenic substrate is recommended for activity assays?

TPP2 is a subtilisin-type serine exopeptidase (EC 3.4.14.10) that releases N-terminal tripeptides from oligopeptide substrates. The most widely used fluorogenic substrate for in vitro activity assays is Ala-Ala-Phe-7-amido-4-methylcoumarin (AAF-AMC), which TPP2 cleaves to release the fluorescent AMC leaving group (Ex 360 nm / Em 460 nm). Substrate concentration should be titrated around a reported Km of ~0.1–0.3 mM for AAF-AMC. GluGluPhe-AMC is an alternative for selectivity profiling. Ensure substrate stocks are prepared in DMSO (<1% final v/v) to avoid activity interference.

What buffer conditions are optimal for a recombinant TPP2 fluorogenic activity assay?

Recombinant TPP2 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and is active in this buffer. For fluorogenic assays, dilute into assay buffer of 50 mM Tris-HCl pH 7.5 or 50 mM HEPES pH 7.4, 100–150 mM NaCl. TPP2 is a serine protease — include 1 mM DTT to maintain reducing conditions and prevent non-specific oxidative inactivation, but avoid metal chelators (EDTA) in the assay well unless specifically testing inhibitor mechanism. Reactions run at 37°C with 30–60 min pre-incubation of enzyme before substrate addition generally yield the most reproducible Vmax measurements.

What starting enzyme concentration should I use when setting up a TPP2 inhibitor IC50 assay?

For a standard AAF-AMC fluorogenic IC50 assay in 96- or 384-well format, start with 2–10 nM recombinant TPP2 per well, titrating inhibitor across 8–10 concentrations spanning at least 3 log units around the anticipated IC50. Confirm that fluorescence signal is linear with enzyme concentration and that substrate turnover remains below 10% at the assay endpoint to satisfy steady-state assumptions. Protein concentration of the supplied stock should be verified by absorbance at A280 or BCA assay before use, as 10% glycerol in the storage buffer can affect some colorimetric methods — account for this when calculating dilutions.

Can I use this recombinant TPP2 as a Western blot positive control with the matched Triple Point Biologics antibody?

Yes — this recombinant is the validated positive-control antigen for the Triple Point Biologics matched rabbit polyclonal antibody (SKU: RP-Tripeptidyl Peptidase2; see /anti-tripeptidyl-peptidase2-rabbit-polyclonal-antibody). The two products are produced in the same laboratory, and compatibility for Western blot has been confirmed. Load 10–50 ng of recombinant TPP2 per lane under reducing SDS-PAGE conditions alongside your cell lysate samples. A clean band at 140–145 kDa in the recombinant lane directly confirms antibody performance and validates any band of equivalent MW observed in experimental lanes.

How much recombinant TPP2 should I load for a Western blot positive control lane?

Load 20–50 ng per lane as a starting point when pairing with the matched RP-Tripeptidyl Peptidase2 rabbit polyclonal antibody (SKU: RP-Tripeptidyl Peptidase2). At this range, a distinct band at ~140–145 kDa is detectable with standard chemiluminescent ECL without saturating the detector, allowing direct comparison to endogenous TPP2 signal in adjacent lysate lanes. If you are running a lower-sensitivity detection system, scale up to 100 ng. Dilute the recombinant stock in 1× Laemmli buffer immediately before use; do not store diluted material, as repeated dilution from frozen aliquots accelerates activity loss.

How should I store and handle recombinant TPP2 to maintain activity, and what is the shelf life?

Store at -20°C in single-use aliquots immediately upon receipt. The supplied buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — is formulated for long-term frozen storage; the glycerol component minimizes freeze-thaw damage. Avoid repeated freeze-thaw cycles: each cycle can reduce measurable exopeptidase activity by 15–30% in our internal validation data. Shelf life is 12 months from date of manufacture when stored correctly. For working dilutions prepared on the day of assay, keep on ice and use within 4–6 hours. Endotoxin is <0.1 EU/µg by LAL, so no additional depyrogenation step is required for cell-based assays.

Validation imagery coming soon

Western blot validation figures for REC-TripeptidylPeptidase2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →